Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has been given a consensus recommendation of “Hold” by the twelve brokerages that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $24.27.
Several equities research analysts have weighed in on MYGN shares. UBS Group assumed coverage on Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price target on the stock. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Bank of America decreased their price target on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a report on Friday, December 13th. Leerink Partnrs cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, Morgan Stanley decreased their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research note on Monday, November 18th.
Check Out Our Latest Analysis on Myriad Genetics
Myriad Genetics Stock Up 0.7 %
Insider Buying and Selling at Myriad Genetics
In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $22.93, for a total transaction of $343,950.00. Following the completion of the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at approximately $22,067,327.54. The trade was a 1.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.
Institutional Trading of Myriad Genetics
A number of institutional investors have recently made changes to their positions in MYGN. GAMMA Investing LLC lifted its holdings in Myriad Genetics by 34.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after purchasing an additional 412 shares in the last quarter. Atria Investments Inc lifted its stake in shares of Myriad Genetics by 5.4% in the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock worth $313,000 after buying an additional 581 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock worth $87,000 after acquiring an additional 583 shares during the last quarter. Arizona State Retirement System boosted its position in Myriad Genetics by 3.4% during the second quarter. Arizona State Retirement System now owns 25,160 shares of the company’s stock worth $615,000 after acquiring an additional 829 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Myriad Genetics by 1.5% during the 2nd quarter. Federated Hermes Inc. now owns 56,807 shares of the company’s stock valued at $1,389,000 after acquiring an additional 846 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Featured Articles
- Five stocks we like better than Myriad Genetics
- What Are Dividends? Buy the Best Dividend Stocks
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- Transportation Stocks Investing
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- How to Choose Top Rated Stocks
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.